Evidence check: CYP2D6 in the context of sleep

CYP2D6 is a key drug-metabolizing enzyme responsible for breaking down about 20–25% of common medications. In the context of sleep, its relevance is indirect: CYP2D6 metabolizes many antidepressants (e.g., tricyclics, some SSRIs) and antipsychotics that can have sedative effects or influence sleep architecture. It also activates opioid prodrugs like codeine and tramadol, which can cause sedation. A poor metabolizer status (e.g., due to rs3892097) leads to higher drug levels for active substances and reduced efficacy for prodrugs. However, direct evidence linking CYP2D6 variants to sleep disorders or sleep quality is limited – no large-scale studies have established a robust association. Most evidence comes from pharmacogenetic and clinical observations. Caveat: a single SNP is not diagnostic; gene–environment interactions dominate. Always consult a physician before adjusting any medication.